BDX241220C340000
- 0.00
- 0.000.00%
Becton Dickinson & Co Newsroom
Unusual Options Activity: SLB, Z and Others Attract Market Bets, SLB V/OI Ratio Reaches 375.0
Express News | BD Says CEO Pay Ratio for 2024 Was 396 to 1
Express News | BD Says CEO Thomas Polen's 2024 Total Compensation Was $17.3 Mln - SEC Filing
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Least Shorted S&P 500 Stocks in November
BDX Stock Down Despite New Expansion to Boost Fingertip Blood Testing
Citi Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Announces Target Price $275
Citi Reaffirms Their Buy Rating on Becton Dickinson (BDX)
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
Express News | Becton, Dickinson And Babson Diagnostics Announced An Expansion Of Fingertip Blood Collection And Testing Technologies For Use By U.S. Health Systems And Other Large Provider Networks In Settings Like Urgent Cares, Doctor Offices, And Other Ambulatory...
BD and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations
BD Resolves Previously Disclosed SEC Investigation Related To Prior Public Disclosures And SEC Reporting Regarding The BD Alaris System; BD Has Agreed To Pay $175M To The SEC; BD Is Not Updating Its Fiscal 2025 Guidance As A Result Of The Settlement
Express News | Becton Dickinson and Co - Not Updating Fiscal 2025 Guidance Due to Settlement
Express News | Becton Dickinson and Co - Resolves SEC Investigation Related to BD Alaris System
BD Resolves Previously Disclosed SEC Investigation
Express News | U.S. SEC Says Becton Dickinson to Pay $175 Million for Misleading Investors About Alaris Infusion Pump
Moderna Remains the Most Shorted Among S&P 500 Healthcare Stocks in November